Silke Gillessen

32.7k total citations · 9 hit papers
250 papers, 9.9k citations indexed

About

Silke Gillessen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Silke Gillessen has authored 250 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Pulmonary and Respiratory Medicine, 89 papers in Oncology and 63 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Silke Gillessen's work include Prostate Cancer Treatment and Research (135 papers), Radiopharmaceutical Chemistry and Applications (58 papers) and Prostate Cancer Diagnosis and Treatment (46 papers). Silke Gillessen is often cited by papers focused on Prostate Cancer Treatment and Research (135 papers), Radiopharmaceutical Chemistry and Applications (58 papers) and Prostate Cancer Diagnosis and Treatment (46 papers). Silke Gillessen collaborates with scholars based in Switzerland, United Kingdom and United States. Silke Gillessen's co-authors include Axel Heidenreich, Alan Horwich, Chris Parker, Marcus Groettrup, Karim Fizazi, Elke Scandella, Glenn Dranoff, Ying Men, Bernard Escudier and Axel Bex and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Silke Gillessen

233 papers receiving 9.8k citations

Hit Papers

Renal cell carcinoma: ESMO Clinical Practice Guidelines... 2015 2026 2018 2022 2019 2021 2020 2021 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2019 774 citations Silke Gillessen et al. Annals of Oncology profile →
  2. Prostate cancer
    2021 663 citations Silke Gillessen et al. profile →
  3. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2020 577 citations Karim Fizazi, Axel Heidenreich et al. Annals of Oncology profile →
  4. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2021 309 citations Tom Powles, Éva Compérat et al. Annals of Oncology profile →
  5. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 297 citations Silke Gillessen, Axel Heidenreich et al. Annals of Oncology profile →
  6. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    2022 157 citations Silke Gillessen, Dana E. Rathkopf et al. profile →
  7. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 99 citations Jourik A. Gietema, Silke Gillessen et al. Annals of Oncology profile →
  8. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2024 96 citations Éva Compérat, Silke Gillessen et al. Annals of Oncology profile →
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
    2024 74 citations Éva Compérat, Silke Gillessen et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silke Gillessen Switzerland 46 4.5k 3.3k 2.7k 2.5k 1.6k 250 9.9k
Douglas A. Arenberg United States 49 3.0k 0.7× 4.1k 1.2× 2.4k 0.9× 3.1k 1.3× 1.0k 0.6× 133 9.5k
Edward M. Schaeffer United States 50 5.7k 1.3× 2.0k 0.6× 2.1k 0.8× 1.5k 0.6× 1.7k 1.0× 294 9.4k
Massimo Aglietta Italy 58 2.8k 0.6× 7.1k 2.2× 3.6k 1.3× 3.0k 1.2× 1.9k 1.2× 397 14.5k
Rolf A. Stahel Switzerland 64 6.9k 1.5× 5.8k 1.8× 4.4k 1.6× 1.5k 0.6× 1.9k 1.2× 326 14.1k
Hirotsugu Uemura Japan 39 3.9k 0.9× 2.1k 0.6× 2.4k 0.9× 774 0.3× 1.3k 0.8× 367 7.1k
Marco Alifano France 52 3.8k 0.9× 4.4k 1.3× 2.1k 0.8× 3.1k 1.3× 1.4k 0.9× 283 11.0k
Aung Naing United States 58 3.0k 0.7× 5.8k 1.8× 4.4k 1.6× 2.1k 0.8× 3.0k 1.9× 483 12.5k
David I. Quinn United States 59 4.8k 1.1× 5.8k 1.8× 4.0k 1.5× 1.4k 0.6× 2.3k 1.4× 420 14.1k
Chikara Οhyama Japan 43 2.6k 0.6× 2.2k 0.7× 3.5k 1.3× 1.5k 0.6× 803 0.5× 524 9.3k
Hideaki Miyake Japan 49 4.7k 1.0× 3.2k 1.0× 4.0k 1.5× 795 0.3× 2.1k 1.3× 620 10.8k

Countries citing papers authored by Silke Gillessen

Since Specialization
Citations

This map shows the geographic impact of Silke Gillessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silke Gillessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silke Gillessen more than expected).

Fields of papers citing papers by Silke Gillessen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silke Gillessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silke Gillessen. The network helps show where Silke Gillessen may publish in the future.

Co-authorship network of co-authors of Silke Gillessen

This figure shows the co-authorship network connecting the top 25 collaborators of Silke Gillessen. A scholar is included among the top collaborators of Silke Gillessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silke Gillessen. Silke Gillessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravi, Praful, Wanling Xie, Silke Gillessen, et al.. (2025). Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer and Prostatic Diseases. 29(1). 202–204. 1 indexed citations
2.
Merler, Sara, Luís Castelo-Branco, Ricardo Pereira Mestre, et al.. (2025). The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages. International Journal of Molecular Sciences. 26(1). 318–318. 1 indexed citations
3.
Fankhauser, Christian D., Marian S. Wettstein, Ailsa J. Christiansen, et al.. (2024). Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels. Urologic Oncology Seminars and Original Investigations. 42(12). 455.e9–455.e13.
4.
Turco, Fabio, Giorgio Treglia, Silke Gillessen, et al.. (2024). Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). e17111–e17111. 1 indexed citations
5.
Gillessen, Silke, Ursula Vogl, Luigi Tortola, et al.. (2024). Antiandrogens as Therapies for COVID-19: A Systematic Review. Cancers. 16(2). 298–298. 4 indexed citations
6.
Kwak, Lucia, Praful Ravi, John G. Armstrong, et al.. (2024). Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. Journal of Clinical Oncology. 42(18). 2132–2138. 6 indexed citations
7.
Bandini, Marco, Éva Compérat, Gert De Meerleer, et al.. (2024). Penile cancer: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 9(7). 103481–103481. 6 indexed citations
8.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. European Urology Oncology. 7(2). 241–247. 6 indexed citations
9.
Omlin, Aurelius, Richard Cathomas, Gunhild von Amsberg, et al.. (2023). Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(10). 1887–1893. 6 indexed citations
10.
Pomykala, Kelsey L., Boris Hadaschik, Oliver Sartor, et al.. (2023). Next generation radiotheranostics promoting precision medicine. Annals of Oncology. 34(6). 507–519. 42 indexed citations
11.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). e441–e442.
12.
Gillessen, Silke, Giuseppe Procopio, Stefanie Hayoz, et al.. (2023). Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). Journal of Clinical Oncology. 41(20). 3608–3615. 2 indexed citations
13.
Turco, Fabio, Silke Gillessen, Giorgio Treglia, et al.. (2023). Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 27(3). 385–392. 4 indexed citations
14.
Wilson, Brooke E., Andrew J. Armstrong, Johann S. de Bono, et al.. (2022). Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer. 170. 296–304. 20 indexed citations
15.
Joshua, Anthony M., Andrew J. Armstrong, Megan Crumbaker, et al.. (2022). Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European Journal of Cancer. 170. 285–295. 21 indexed citations
16.
Rossi, Lorenzo, Ricardo Pereira Mestre, Mauro Manconi, et al.. (2022). Prostate Cancer and Sleep Disorders: A Systematic Review. Cancers. 14(7). 1784–1784. 14 indexed citations
17.
Beyer, J., Dominik Berthold, Richard Cathomas, et al.. (2021). Swiss germ-cell cancer consensus recommendations. Swiss Medical Weekly. 151(3334). w30023–w30023. 1 indexed citations
18.
Martorana, Federica, Ilaria Colombo, Giorgio Treglia, Silke Gillessen, & Anastasios Stathis. (2021). A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews. 101. 102300–102300. 10 indexed citations
19.
Prior, John O., Silke Gillessen, Manfred P. Wirth, et al.. (2017). Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy. European Journal of Cancer. 77. 127–139. 11 indexed citations
20.
Gillessen, Silke & Florian Strasser. (2006). Treatment possibilities for patients with advanced prostate cancer. 63(2). 157–162. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas A. Arenberg Breakdown of academic impact, for papers by Edward M. Schaeffer Breakdown of academic impact, for papers by Massimo Aglietta Breakdown of academic impact, for papers by Rolf A. Stahel Breakdown of academic impact, for papers by Hirotsugu Uemura Breakdown of academic impact, for papers by Marco Alifano Breakdown of academic impact, for papers by Aung Naing Breakdown of academic impact, for papers by David I. Quinn Breakdown of academic impact, for papers by Chikara Οhyama Breakdown of academic impact, for papers by Hideaki Miyake
Rankless by CCL
2026